1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 05/18 10:05:43 am
64.105 EUR   -0.02%
05/16China's LongPing to launch Brazil sorghum seed next year
RE
05/11GE medical dye shortage felt beyond US as German hospital affected
RE
05/11BAYER AG : Gets a Buy rating from Jefferies
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology

01/10/2022 | 02:30am EDT

Bayer AG and Mammoth Biosciences, Inc. announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth Biosciences’ ground breaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer’s efforts to develop transformative therapies for patients faster and strengthen the company’s recently established new cell and gene therapy platform. Under the terms of the agreement the two companies will start their collaboration with a focus on liver-targeted diseases. Cell and gene therapies are the next step in the evolution of drug development. By addressing the root cause of diseases, they are potentially capable of permanently reversing diseases with a one-time treatment. Gene editing serves as a key enabler for cell therapies when used outside the living body (ex vivo) and allows therapeutic targeting of a wide range of genetic diseases with a high unmet medical need when used inside the living body (in vivo). Mammoth Biosciences’ proprietary toolkit of ultra-small Cas enzymes, including Cas14 and Cas?, allows for expanded high-fidelity gene editing to be combined with targeted systemic delivery. Under the agreement, Bayer gains access to this novel gene-editing technology, which offers the potential of an advanced in vivo applicability due to the ultra-compact size of these novel CRISPR systems.


© S&P Capital IQ 2022
All news about BAYER AG
05/16China's LongPing to launch Brazil sorghum seed next year
RE
05/11GE medical dye shortage felt beyond US as German hospital affected
RE
05/11BAYER AG : Gets a Buy rating from Jefferies
MD
05/11EUROPE : European stocks log best session in 6 weeks as cyclicals roar back
RE
05/11BAYER AG : Credit Suisse remains Neutral
MD
05/11BAYER AG : DZ Bank remains its Buy rating
MD
05/11BAYER AG : Buy rating from Goldman Sachs
MD
05/11BAYER AG : Bernstein gives a Buy rating
MD
05/11BAYER AG : Buy rating from UBS
MD
05/11BAYER AG : Berenberg maintains a Buy rating
MD
More news
Analyst Recommendations on BAYER AG
More recommendations
Financials
Sales 2022 47 581 M 50 117 M 50 117 M
Net income 2022 4 996 M 5 262 M 5 262 M
Net Debt 2022 33 102 M 34 866 M 34 866 M
P/E ratio 2022 12,7x
Yield 2022 3,45%
Capitalization 62 993 M 66 350 M 66 350 M
EV / Sales 2022 2,02x
EV / Sales 2023 1,91x
Nbr of Employees 100 753
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | MarketScreener
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 64,12 €
Average target price 77,40 €
Spread / Average Target 20,7%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board & CEO
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG36.43%66 350
JOHNSON & JOHNSON4.53%470 547
PFIZER, INC.-13.06%288 063
ABBVIE INC.14.31%273 513
ELI LILLY AND COMPANY9.12%271 308
ROCHE HOLDING AG-14.97%263 868